Leaflet LYNPARZA 100mg film-coated tablets
Indicated for: cancer
Substance: olaparib (PARP inhibitor)
ATC: L01XX46 (Antineoplastic and immunomodulating agents | Other antineoplastic agents)
Olaparib is a medication used for the treatment of certain types of cancer, such as ovarian, breast, or prostate cancer, associated with BRCA gene mutations. It is a poly(ADP-ribose) polymerase (PARP) inhibitor that interferes with DNA repair in cancer cells, leading to their death.
The medication is taken orally, usually twice daily, as directed by your doctor. It is important to follow the treatment regimen and undergo regular check-ups to monitor effectiveness and potential side effects.
Side effects may include nausea, fatigue, anemia, diarrhea, or, in rare cases, myelodysplastic syndrome.
Patients should inform their doctor about any other medications being used or pre-existing conditions to ensure the safe use of olaparib.
General data about LYNPARZA 100mg
- Substance: olaparib
- Date of last drug list: 01-05-2026
- Commercial code: W64660001
- Concentration: 100mg
- Pharmaceutical form: film-coated tablets
- Quantity: 56
- Product type: original
- Price: 7281.69 RON
- Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Pharmaceutical forms available for olaparib
Concentrations available for olaparib
- 100mg
- 150mg
- 50mg
